newsfilter
← Latest News
Business Wire·

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

  • The FDA issued a Complete Response Letter regarding Summit Therapeutics' Biologics License Application for ivonescimab combined with chemotherapy for previously treated locally advanced or metastatic non-small cell lung cancer patients.
  • The BLA was not approved because the FDA determined that substantial evidence of effectiveness is not established without a statistically significant improvement in overall survival.
  • While the HARMONi Phase III trial met its primary progression-free survival endpoint, the primary analysis for overall survival did not achieve statistical significance despite showing a positive trend.
  • Post-hoc analyses of longer-term follow-up data showed a consistent overall survival benefit across western patients, Asian patients, & the full population with a hazard ratio of 0.76.
  • Ivonescimab demonstrated an acceptable safety profile with manageable adverse events, comparable discontinuation rates between treatment arms, & low rates of death due to treatment-related adverse events.
  • Summit Therapeutics confirmed its continued commitment to advancing ivonescimab development across multiple other indications including colorectal cancer, urothelial carcinoma, & renal cell carcinoma.
  • The company is conducting additional Phase III trials such as HARMONi-3, HARMONi-7, HARMONi-GI3, & HARMONi-GU1 to evaluate ivonescimab in various first-line & combination settings.
  • Strategic collaborations are ongoing with AstraZeneca, Daiichi Sankyo, Revolution Medicines, GSK, & Arcus Biosciences to test ivonescimab combined with other novel compounds in breast cancer, gastrointestinal tumors, & solid tumors.
  • Cooperative group studies are planned with GORTEC & ECOG-ACRIN to evaluate ivonescimab in head and neck squamous cell carcinoma & biliary tract cancer.
  • Ivonescimab is an investigational PD-1 x VEGF bispecific antibody initially approved in China in May 2024 but remains unapproved by regulatory authorities in the United States or Europe.